Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Stock Information for Coya Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Coya Therapeutics Inc.

Coya Therapeutics Announces $11.1 Million Private Placement
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.